Pharmaceutical - Eisai

Filter

Current filters:

Eisai

Popular Filters

1 to 25 of 124 results

Eisai's Halaven to stay on UK Cancer Drugs Fund list pending reconsideration

Eisai's Halaven to stay on UK Cancer Drugs Fund list pending reconsideration

11-03-2015

Japanese drug major Eisai has announced that its drug Halaven (eribulin) will remain on the UK's National…

EisaiHalavenOncologyPharmaceuticalRegulationUK

Eisai and Merck enter cancer research collaboration

05-03-2015

Japanese drug major Eisai saw its shares gain 7.15% to 6,732 yen after it announced it had entered into…

EisaiHalavenKeytrudaLenvimaMerck & CoOncologyPharmaceuticalResearch

First launch for Eisai’s Lenvima, in the USA

First launch for Eisai’s Lenvima, in the USA

03-03-2015

The US subsidiary of Japanese pharma major Eisai has now launched its in-house developed novel anticancer…

EisailenvatinibLenvimaMarkets & MarketingOncologyPharmaceuticalRare diseases

UPDATE: FDA approves Eisai’s Lenvima for a type of thyroid cancer and expands use of Banzel

UPDATE: FDA approves Eisai’s Lenvima for a type of thyroid cancer and expands use of Banzel

14-02-2015

The US Food and Drug Administration on Friday granted approval for Japanese pharma major Eisai’s Lenvima…

BanzelEisailenvatinibLenvimaNeurologicalOncologyPharmaceuticalRare diseasesRegulationUSA

Eisai's lenvatinib shows statistically-significant progression-free survival in Ph III trial

Eisai's lenvatinib shows statistically-significant progression-free survival in Ph III trial

13-02-2015

Japanese drug major Eisai has published results of its SELECT Phase III study, showing its lenvatinib…

EisaiHealthJapanlenvatinibPharmaceuticalWeakness

Helsinn grants Stendhal rights to NEPA in several Latin America countries

02-02-2015

Family-run Swiss oncology specialist Helsinn has granted exclusive rights to Mexico-based Especificos…

AkynzeoEisaiHelsinnLicensingNEPAnetupitantOncologypalonosetronPharmaceuticalSouth AmericaStendhal

German Federal Joint Committee confirms 'considerable' benefit of Eisai's Halaven in breast cancer

German Federal Joint Committee confirms 'considerable' benefit of Eisai's Halaven in breast cancer

23-01-2015

The German Federal Joint Committee has confirmed the ‘considerable’ additional benefit of Japanese…

EisaiGermanyHalavenOncologyPharmaceuticalRegulation

Eisai launches epilepsy treatment Exalief in Russia

Eisai launches epilepsy treatment Exalief in Russia

20-01-2015

Japanese drug major Eisai has announced that epilepsy drug Exalief (eslicarbazepine acetate) will soon…

EisaiExaliefMarkets & MarketingNeurologicalPharmaceuticalRussia

Eisai's Fycompa for refractory partial-onset seizures meets Phase III trial primary endpoint

Eisai's Fycompa for refractory partial-onset seizures meets Phase III trial primary endpoint

05-01-2015

Japanese drug major Eisai has announced a Phase III trial of antiepileptic drug Fycompa (perampanel)…

EisaiFycompaJapanNeurologicalperampanelPharmaceuticalResearch

Eisai's Halaven now available in Russia for advanced breast cancer

Eisai's Halaven now available in Russia for advanced breast cancer

18-12-2014

Halaven (eribulin) manufactured by Japanese drug major Eisai is now available in Russia.

EisaiHalavenOncologyPharmaceuticalRegulationRussia

Eisai opens new parenteral facility in China

29-11-2014

Japanese pharma major Eisai (TYO: 4523) said on Friday that construction of a new production facility…

ChinaEisaiMethycobalNeurologicalPharmaceuticalProduction

Eisai opens £8 million packaging facility in UK

Eisai opens £8 million packaging facility in UK

26-11-2014

Japanese drug major Eisai has opened a new facility at its EMEA Knowledge Center in Hatfield, UK, to…

EisailenvatinibPharmaceuticalProductionUK

Eisai’s Zonegran safety in pediatric patients confirmed by pooled data analysis

Eisai’s Zonegran safety in pediatric patients confirmed by pooled data analysis

10-11-2014

The safety profile of adjunctive Japanese drugmaker Eisai’s Zonegran (zonisamide) in pediatric patients…

EisaiEuropeNeurologicalPharmaceuticalResearchZonegran

Eisai “dismayed” by G-BA decision on Fycompa

06-11-2014

Japanese drug major Eisai has expressed “utmost disappointment” that the German Federal Joint Committee…

EisaiFycompaGermanyNeurologicalPharmaceuticalPricingRegulation

IQWIG confirms an additional benefit of Eisai's Halaven

IQWIG confirms an additional benefit of Eisai's Halaven

04-11-2014

Following a benefit:cost re-assessment, the German Institute for Quality and Efficiency in Health Care…

EisaiGermanyHalavenOncologyPharmaceuticalPricingRegulation

Eisai's Fycompa launches in Australia for seizures

Eisai's Fycompa launches in Australia for seizures

03-11-2014

Fycompa (perampanel), manufactured by Japanese drug major Eisai, has been approved for reimbursement…

AustraliaEisaiFycompaNeurologicalPharmaceuticalRegulation

FDA accepts Eisai's supplemental New Drug Application for Fycompa in tonic-clonic seizures

FDA accepts Eisai's supplemental New Drug Application for Fycompa in tonic-clonic seizures

20-10-2014

Japanese drug major Eisai has had a supplemental New Drug Application for its in-house-discovered AMPA…

CNS DiseasesEisaiFycompaJapanPharmaceuticalRegulation

R&D success is in the cloud

R&D success is in the cloud

17-10-2014

Here's our take on the week's top stories.

EisaiGlobalMerckMerck & CoPfizerPharmaceuticalResearch

FDA grants priority reviews for Eisai's for rufinamide and lenvatinib

FDA grants priority reviews for Eisai's for rufinamide and lenvatinib

15-10-2014

There was good news for Japanese drugmaker Eisai yesterday, as the US Food and Drug Administration granted…

BanzelEisailenvatinibNeurologicalOncologyPharmaceuticalRegulationRufinamide TabletsUSA

FDA approves Eisai’s Akynzeo for CINV

13-10-2014

The US Food and Drug Administration has approved Japanese pharma major Eisai’s Akynzeo (netupitant…

AkynzeoEisaiHelsinnnetupitantOncologypalonosetronPharmaceuticalRegulationUSA

Hikma to distribute Eisai’s Fycompa in Middle East

13-10-2014

Hikma Pharmaceuticals has entered into a partnership with Japanese pharma major Eisai for the distribution…

EisaiFycompaHikma PharmaceuticalsJordanLicensingMarkets & MarketingNeurologicalPharmaceuticalRest of the WorldSaudi Arabia

French Transparency Commission recognizes efficacy of Eisai’s Zonegran monotherapy

French Transparency Commission recognizes efficacy of Eisai’s Zonegran monotherapy

06-10-2014

Transparency advice for Japanese pharma major Eisai’s Zonegran (zonisamide) monotherapy in the treatment…

EisaiFranceNeurologicalPharmaceuticalRegulationZonegran

1 to 25 of 124 results

Back to top